Terms: = Uterine cancer AND NOTCH1, TAN1, P46531, 4851, ENSG00000148400, hN1 AND Clinical Outcome
2 results:
1. MEK inhibition overcomes resistance to EphA2-targeted therapy in uterine cancer.
Wu Y; Huang J; Ivan C; Sun Y; Ma S; Mangala LS; Fellman BM; Urbauer DL; Jennings NB; Ram P; Coleman RL; Hu W; Sood AK
Gynecol Oncol; 2021 Oct; 163(1):181-190. PubMed ID: 34391578
[TBL] [Abstract] [Full Text] [Related]
2. Mutation profiling of uterine cervical cancer patients treated with definitive radiotherapy.
Yoshimoto Y; Sasaki Y; Murata K; Noda SE; Miyasaka Y; Hamamoto J; Furuya M; Hirato J; Suzuki Y; Ohno T; Tokino T; Oike T; Nakano T
Gynecol Oncol; 2020 Nov; 159(2):546-553. PubMed ID: 32951893
[TBL] [Abstract] [Full Text] [Related]
